Article Sidebar
Downloads
Main Article Content
Abstract
Schizophrenia is a disorder of strange and disordered thoughts, delusions, hallucinations, inappropriate influences, and disorders of psychosocial functioning. One of the management of schizophrenia therapy is the administration of atypical antipsychotic drugs, namely clozapine. Clozapine is an antagonist of serotonin (5-HT2) and dopamine type 2 (D2) receptors. However, the risk of using clozapine provides a risk of side effects in the form of metabolic syndromes such as impaired blood glucose regulation and disorders of blood elements such as leukocytes and platelets. This study aims to determine the effect of using clozapine on blood glucose, leukocyte, and platelet levels in schizophrenia patients at Banyumas General Hospital. This research method was carried out by cross-sectional study in outpatient schizophrenia at Banyumas General Hospital who received clozapine therapy and had met the inclusion and exclusion criteria, taken by consecutive sampling, then examined blood glucose levels, leukocyte counts, and platelet counts before and after giving clozapine therapy. Samples were taken on day 1 and day 10 of drug use. Paired t-test statistical analysis was used to see the effect of using clozapine on glucose, leucocyte, and platelet levels. In the T-test, it was found that there was a relationship between the use of clozapine on the patient's blood glucose levels, the use of clozapine did not have a significant effect on the increase in leukocyte levels and there was also a relationship between the use of clozapine and the patient's platelet levels. The results showed that the patient had an increase in blood glucose levels by a percentage (100%), the patient had leukopenia by a percentage (63.5%), the patient had thrombocytopenia by a percentage (75%), while the other patients had thrombocytosis. Patients with hyperglycemia, leucopenia, and thrombocytopenia were those who used clozapine> 12 months
Keywords
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
References
-
Cashen, A. F. dan Tine, B. A. Van (2016) The Washington Manual Hematology and Oncology Subspecialty Consult. 4th ed. Philadelphia: Wolters Kluwer.
Dipiro, J. T. et al. (2017) “Pharmacotherapy: A Pathophysiology Approach, 10th Edition,” Mc-Graw Hill Medical.
Dipiro, J. T. et al. (2020) Pharmacotherapy: A Pathophysiologic Approach. 11th Edition. 11 ed, Mc-Graw Hill Medical. 11 ed. New York: McGraw-Hill Medical. doi: 10.1002/jppr1997274340.
Goldstein, J. I. et al. (2015) “HHS Public Access.” doi: 10.1038/ncomms5757.Clozapine-induced.
Halgin, R. P. dan Whitbourne, S. K. (2010) Psikologi Abnormal: Perspektif Klinis pada Gangguan Psikologis. Jakarta: Salemba Humanika.
Herceg, M., Mužinić, L. dan Jukić, V. (2010) “Can we prevent blood dyscrasia (leucopenia, thrombocytopenia) and epileptic seizures induced by clozapine,” in Psychiatria Danubina.
Ikawati, Z. (2015) Pengantar Farmakologi Molekuler. Yogyakarta: Universitas Gadjah Mada Press.
Jarut, Y. M., Fatimawali dan Wiyono, W. I. (2013a) “Tinjauan Penggunaan Antipsikotik Pada Pengobatan Skizofrenia Di Rumah Sakit Prof . Dr . V . L. Ratumbuysang Manado Periode Januari 2013- Maret 2013,” Jurnal Ilmiah Farmasi, 2(03), hal. 54–57.
Jarut, Y. M., Fatimawali dan Wiyono, W. I. (2013b) “Tinjauan Penggunaan Antipsikotik Pada Pengobatan Skizofrenia Di Rumah Sakit Prof . Dr . V . L. Ratumbuysang Manado Periode Januari 2013- Maret 2013,” Jurnal Ilmiah Farmasi.
Kartika, Y., Saida, S. A. dan Nola (2020) “Universitas Abulyatama Gambaran Kadar Gula Darah Pasien Skizofrenia Tipe Paranoid yang Menggunakan Clozapine,” Jurnal Riset dan Inovasi Pendidikan, 2(1), hal. 108–115.
Kemenkes RI; BRIN (2018) “Hasil Utama Riset Kesehatan Dasar,” Kementrian Kesehatan Republik Indonesia, hal. 1–100. Tersedia pada: http://www.depkes.go.id/resources/download/info-terkini/hasil-riskesdas-2018.pdf.
Legge, S. E. dan Walters, J. T. (2019) “Genetics of clozapine-associated neutropenia: Recent advances, challenges and future perspective,” Pharmacogenomics, 20(4), hal. 279–290. doi: 10.2217/pgs-2018-0188.
Li, R. et al. (2016) “Why sex differences in schizophrenia? HHS Public Access,” J Transl Neurosci (Beijing), 1(1), hal. 37–42.
Lopez Vicchi, F. et al. (2016) “Dopaminergic drugs in type 2 diabetes and glucose homeostasis,” Pharmacological Research. doi: 10.1016/j.phrs.2015.12.029.
Mueser, K. T. dan Jeste, D. V. (2008) Clinical Handbook of Schizophrenia. Diedit oleh The Guilford Press. New York.
Ochoa, S. et al. (2012) “Gender Differences in Schizophrenia and First-Episode Psychosis: A Comprehensive Literature Review,” Schizophrenia Research and Treatment, 2012, hal. 1–9. doi: 10.1155/2012/916198.
Sadock, B. J. dan Saddock, V. A. (2005) Kaplan and Sadock’s Comprehensive Textbook of Psychiatry, vol 1, Psychiatry: Interpersonal and Biological Processes.
Sadock, B., Sadock, V. dan Ruuiz, P. (2019) Kaplan & Sadock’s Synopsis of Psychiatry, Journal of Chemical Information and Modeling.